



## **Serina Therapeutics Publishes Invited Manuscript on Tuning Drug Delivery via its Proprietary Polymer Technology**

Huntsville, AL, October 10th, 2019

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary drug delivery technology platform, announced today it has published an important paper on “Tuning drug release from polyoxazoline-drug conjugates” in the European Journal of Polymer Chemistry. The invited paper is published by Elsevier Ltd. in a special edition of “PEOx and polypeptides”. <https://doi.org/10.1016/j.eurpolymj.2019.109241>

“Poly(2-oxazolines) or POZ™ have the ability to solubilize, stabilize and deliver small molecule drugs at steady-state blood levels over a period of days and weeks,” said Dr. J. Milton Harris, the leading author on the paper and a noted scientist in the area of polymer chemistry. “POZ polymers have the ability to fold and interact with both hydrophobic and hydrophilic drugs thereby creating a unique drug delivery molecule”.

Serina has applied the POZ technology in a number of their products including SER-214, a molecule in Phase Ib clinical studies to treat patients with early onset of Parkinson’s disease. Other molecules in the pipeline are SER-241 for late stage Parkinson’s disease, SER-227 for post-operative pain, SER-228 for refractory epilepsy and SER-232 for chemotherapy induced nausea and vomiting.

### **About Serina**

Serina Therapeutics is a privately held pharmaceutical company located at the HudsonAlpha Institute for Biotechnology in Huntsville, AL that is developing novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology. The founders and managers of Serina were formerly the principals of Shearwater Polymers which enabled fourteen approved polyethylene glycol (PEG) products for various pharmaceutical partners. POZ™ technology provides strong differential characteristics that may demonstrate improved safety, tolerability and clinical benefits versus PEG and other polymer-based technologies. In addition to a growing pipeline of proprietary programs focused on pain, Parkinson’s disease and epilepsy Serina seeks partnership opportunities with pharmaceutical companies to further unlock the promise of the POZ™ platform. For more information on Serina Therapeutics, please visit <http://www.serinatherapeutics.com>.